NAP enhances ADNP binding to microtubule end binding protein (EB1 and EB3) (25), in turn augmenting Tau microtubule interactions, protecting against tauopathy, even in the face of ADNP mutations, such as the prevalent mutation, p.Arg730* (13–15). The gene discussed is MAPT; the disease is tauopathy.